An observational study in Stomach Neoplasms and Aged, sponsored by Chang-Ming Huang, Prof.. Completed at 1 site in China. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2024-05-01.
Sponsored by Chang-Ming Huang, Prof. · Observational
This study aims to develop and validate a Random Survival Forest (RSF) model for predicting long-term survival in elderly patients following curative resection for gastric cancer. The study is a retrospective multi-center analysis involving patients aged 75 and above who underwent gastric resection from January 2009 to December 2018 at nine top-tier hospitals in China. An online prognostic tool is introduced to assist clinicians in predicting patient prognosis and customizing treatment and follow-up strategies.
This retrospective multi-center study focuses on the development and validation of a predictive model for elderly gastric cancer patients. Data were collected from 16,344 gastric cancer patients, with 1,202 elderly patients ultimately included after applying exclusion criteria. Patients were randomly divided into training and testing cohorts in a 7:3 ratio. The study was approved by the institutional review boards with a waiver of informed consent due to the use of anonymized secondary data.
The analysis employs the Random Survival Forest (RSF) method, incorporating variable importance and minimal depth techniques to select key variables for predicting overall survival (OS) and disease-free survival (DFS). The study also implements rigorous data handling procedures, including multiple imputations for missing data.
The development of an online prognostic tool based on the RSF model is part of the project, designed to provide real-time survival predictions through a user-friendly interface for clinical application.
2,914 studies on the registry are indexed under Stomach Neoplasms; 881 are open to participants now.
This study's enrollment of 1,202 is above the median of 281 across 684 observational studies indexed under Stomach Neoplasms.
Browse Stomach Neoplasms studies →Chang-Ming Huang, Prof. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population comprises elderly patients, aged 75 and above, diagnosed with gastric cancer and who underwent curative gastrectomy within a ten-year period from January 2009 to December 2018. The participants were selected from nine major tertiary care centers across China, ensuring a comprehensive representation of the demographic. The selection criteria were strictly adhered to, ensuring a uniform and high-quality dataset for subsequent analysis in developing a robust prognostic model. The study's focus on the elderly demographic addresses a significant gap in prognostic tools for this age group, which often presents with distinct clinical and therapeutic challenges.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
5-Year Overall Survival
The proportion of patients who are alive at five years after treatment for elderly gastric cancer patients.
Time frame: 5 years or 60 months.
5-Year Disease-Free Survival
The proportion of patients who have survived without any signs or symptoms of gastric cancer for five years after the initial treatment.
Time frame: 5 years or 60 months.
3-Year Overall Survival
The proportion of patients who have survived without any signs or symptoms of gastric cancer for 3 years after the initial treatment.
Time frame: 3 years or 36 months.
1-Year Overall Survival
The proportion of patients who have survived without any signs or symptoms of gastric cancer for 1 years after the initial treatment.
Time frame: 1 years or 12 months.
3-Year Disease-Free Survival
The proportion of patients who have survived without any signs or symptoms of gastric cancer for 3 years after the initial treatment.
Time frame: 3 years or 36 months.
1-Year Disease-Free Survival
The proportion of patients who have survived without any signs or symptoms of gastric cancer for 1 years after the initial treatment.
Time frame: 1 years or 12 months.
Ran from Jan 2024 to primary completion in Apr 2024, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chang-Ming Huang, Prof.